Last reviewed · How we verify
somatotropin
At a glance
| Generic name | somatotropin |
|---|---|
| Also known as | Genotropin, Growth hormone, Penfill®, rhGH, Saizen |
| Sponsor | Rebecca Knickmeyer Santelli, PhD |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (PHASE3)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance (PHASE2)
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- somatotropin CI brief — competitive landscape report
- somatotropin updates RSS · CI watch RSS
- Rebecca Knickmeyer Santelli, PhD portfolio CI